Cytokinetics Presents Additional Data From Assessment Comparing Aficamten To Placebo On Cardiac Endpoints In Adults With Non-Obstructive HCM At HFSA Annual Scientific Meeting 2026

Cytokinetics, Incorporated (NASDAQ: CYTK) presented additional data from the ACACIA-HCM study at the HFSA Annual Scientific Meeting 2026, focusing on the exercise performance, treatment effect, dose titration, and safety of Aficamten in adults with non-obstructive hypertrophic cardiomyopathy (HCM). The findings further characterize the impact of Aficamten compared to placebo on cardiac endpoints.